Oxurion NV (EBR: OXUR)
Belgium
· Delayed Price · Currency is EUR 0.320
+0.030 (10.34%)
Nov 22, 2024, 5:35 PM CET
Oxurion NV Company Description
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness.
It focuses on developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration.
The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018.
Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Oxurion NV
| Country | Belgium |
| Founded | 1991 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Pascal Ghoson |
Contact Details
Address: Gaston Geenslaan 1 Leuven, 3001 Belgium | |
| Phone | 32 1 675 13 10 |
| Website | oxurion.com |
Stock Details
| Ticker Symbol | OXUR |
| Exchange | Euronext Brussels |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | BE0003846632 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Pascal Ghoson | Chief Executive Officer, Chief Financial Officer and Executive Director |
| Philippe Barbeaux Ph.D. | Chief Scientific Officer |
| Dr. Andy De Deene M.B.A., M.D. | Chief Development Officer |